Literature DB >> 12423624

IL-6-overexpression brings about growth impairment potentially through a GH receptor defect.

Jaroslava Lieskovska1, Donglin Guo, Eva Derman.   

Abstract

This paper is concerned with growth retardation associated with overproduction of interleukin-6 (IL-6). As a model, we used MUP/hIL-6 transgenic mice in which human IL-6 cDNA is overexpressed under the control of a MUP gene enhancer/promoter. The growth-retardation of MUP/hIL-6 transgenic mice was paralleled by reduced serum levels of IGF-I. As shown, hepatic IGF-I mRNA levels were reduced in the transgenic mice. MUP/hIL-6 transgenic mice are in a state of growth hormone (GH)-resistance, since their serum GH levels are either normal or elevated. To identify possible steps in GH signaling which might be perturbed in the transgenic mice, we examined the synthesis of GH receptor (GHR) mRNA. We noted a twofold reduction of hepatic GHR mRNA in the transgenic mice. We therefore conclude that overexpression of IL-6 brings about growth impairment in part through a GH receptor defect.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12423624     DOI: 10.1016/s1096-6374(02)00079-5

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  9 in total

Review 1.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

2.  Dragon (repulsive guidance molecule b) inhibits IL-6 expression in macrophages.

Authors:  Yin Xia; Virna Cortez-Retamozo; Vera Niederkofler; Rishard Salie; Shanzhuo Chen; Tarek A Samad; Charles C Hong; Silvia Arber; Jatin M Vyas; Ralph Weissleder; Mikael J Pittet; Herbert Y Lin
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

Review 3.  Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis.

Authors:  Shumpei Yokota; Takako Miyamae; Tomoyuki Imagawa; Shigeki Katakura; Rumiko Kurosawa; Masaaki Mori
Journal:  Clin Rev Allergy Immunol       Date:  2005-06       Impact factor: 8.667

4.  Association of TGFB1 29C/T and IL6 -572G/C polymorphisms with developmental hip dysplasia: a case-control study in adults with severe osteoarthritis.

Authors:  Tomislav Čengić; Vladimir Trkulja; Sandra Kraljević Pavelić; Ivana Ratkaj; Elitza Markova-Car; Michele Mikolaučić; Robert Kolundžić
Journal:  Int Orthop       Date:  2015-01-22       Impact factor: 3.075

5.  Human IL6 enhances leptin action in mice.

Authors:  M Sadagurski; L Norquay; J Farhang; K D'Aquino; K Copps; M F White
Journal:  Diabetologia       Date:  2009-11-10       Impact factor: 10.122

6.  Skeletal muscle growth in young rats is inhibited by chronic exposure to IL-6 but preserved by concurrent voluntary endurance exercise.

Authors:  P W Bodell; E Kodesh; F Haddad; F P Zaldivar; D M Cooper; G R Adams
Journal:  J Appl Physiol (1985)       Date:  2008-12-04

7.  Distinct mechanisms of induction of hepatic growth hormone resistance by endogenous IL-6, TNF-α, and IL-1β.

Authors:  Yueshui Zhao; Xiaoqiu Xiao; Stuart J Frank; Herbert Y Lin; Yin Xia
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-06-03       Impact factor: 4.310

8.  The effect of exercise on IL-6-induced cachexia in the Apc ( Min/+) mouse.

Authors:  Melissa J Puppa; James P White; Kandy T Velázquez; Kristen A Baltgalvis; Shuichi Sato; John W Baynes; James A Carson
Journal:  J Cachexia Sarcopenia Muscle       Date:  2011-11-30       Impact factor: 12.910

Review 9.  Tocilizumab in the treatment of systemic juvenile idiopathic arthritis.

Authors:  Miho Murakami; Minako Tomiita; Norihiro Nishimoto
Journal:  Open Access Rheumatol       Date:  2012-07-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.